CompletedNot Applicable

Muscle and Fat Mass in Preoperative Computed Tomography and a Neuromuscular Blocking Agent Dose

South Korea31 participantsStarted 2021-01-01

Plain-language summary

Deep neuromuscular blockade has benefits in various surgical procedures and reduces postoperative pain. While neuromuscular blockade dosages are often based on the patient's actual body weight, body composition can vary significantly depending on age, gender, and individual exercise levels. Therefore, uniformly estimating neuromuscular blockade dosages based on actual body weight can result in under- or over-administered neuromuscular blocking agents. Calculating neuromuscular blockade dosage based on actual body weight can be inaccurate, but it remains due to the difficulty of accurately quantifying human muscle and fat mass. Recent advances in image analysis techniques utilizing artificial intelligence models have led to the development of methods for quantifying muscle and fat mass from computed tomography (CT). Theoretically, a higher neuromuscular blockade dosage should be required as the muscle mass increases. This study aims to analyze the relationship between neuromuscular blocking agent dosage, onset time, profound blockade time, and recovery time, and muscle mass and fat mass calculated from preoperative CT scans.

Who can participate

Age range

19 Years – 85 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * American Society of Anesthesiologists physical class (ASA class) 1-3 * Patients scheduled for elective gynecologic surgery under general anesthesia * Patients undergoing abdominal computed tomography for routine preoperative preparation Exclusion Criteria: * Pregnant women * Decreased renal function (GFR\<60mL/min/1.73m2). * Patients taking drugs that affect deep neuromuscular blockade * Patients with a history of neuromuscular and muscle disorders

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

muscle and fat mass

Timeframe: intraoperative period

Trial details

NCT IDNCT07478120

SponsorSeoul National University Bundang Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-02-28

View on ClinicalTrials.gov More Neuromuscular Blockade trials